Treatment of pre- and postmenopausal Women with HR+/HER2-metastatic Breast Cancer Ribociclib receives high AGO Recommendation Level

被引：0
|
作者：
Rudesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [41] Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment
    Arpino, Grazia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Lambertini, Matteo
    Igidbashian, Sarah
    Bellini, Martina
    Giuntoli, Serena
    Guillaume, Xavier
    Behillil, Julie
    Graziani-Taugeron, Claire
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [43] Treatment patterns for young women with HR+/HER2-metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
    Burstein, Harold J.
    Mayer, Erica L.
    DeMichele, Angela
    Harnett, James
    Mardekian, Jack
    McRoy, Lynn
    Bartlett, Cynthia Huang
    Koehler, Maria
    Rimawi, Mothaffar Fahed
    CANCER RESEARCH, 2018, 78 (04)
  • [44] Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2-metastatic breast cancer
    Lambrechts, Yentl
    Hatse, Sigrid
    Kenis, Cindy
    Decoster, Lore
    de Azambuja, Evandro
    Jerusalem, Guy
    Neven, Patrick
    Dal Lago, Lissandra
    Denys, Hannelore
    Vuylsteke, Peter
    Cornelis, Frank
    Punie, Kevin
    Floris, Giuseppe
    Desmedt, Christine
    Laenen, Annouschka
    Ponde, Noam
    Wildiers, Hans
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama
    Castillo-Fernandez, Omar O.
    Lim, Maria
    Montano, Lilian
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Impact of hormone receptor expression level in HR+/HER2-metastatic breast cancer in the large French ESME cohort
    Alexandre, Marie
    Castan, Florence
    Rouge, Thibault De La Motte
    Mailliez, Audrey
    Brain, Etienne
    Bachelot, Thomas
    Arnedos, Monica
    Dalenc, Florence
    Ferrero, Jean-Marc
    Massard, Vincent
    Desmoulins, Isabelle
    Mouret-Reynier, Marie-Ange
    Levy, Christelle
    Goncalves, Anthony
    Berghian, Anca
    Savoye, Aude-Marie
    Frenel, Jean-Sebastien
    Bosquet, Lise
    Delaloge, Suzette
    Jacot, William
    CANCER RESEARCH, 2024, 84 (09)
  • [47] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [48] Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer
    Guerin, Annie
    Goldschmidt, Debbie
    Small, Tania
    Gagnon-Sanschagrin, Patrick
    Romdhani, Hela
    Gauthier, Genevieve
    Kelkar, Sneha
    Wu, Eric Q.
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (08) : 1251 - 1264
  • [49] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
  • [50] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
12345